DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Phase 1

Terminated

Conditions: ALK-positive Non-small Cell Lung Cancer (NSCLC)
RET-positive Non-small Cell Lung Cancer (NSCLC)
RET-positive Thyroid Cancer

Interventions: Drug: Alectinib

First Posted Date: 2017-04-27

Last Posted Date: 2021-09-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT03131206

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 1 locations

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Abemaciclib

First Posted Date: 2017-04-26

Last Posted Date: 2024-11-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT03130439

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Phase 1

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Gefitinib
Drug: Osimertinib

First Posted Date: 2017-04-21

Last Posted Date: 2024-05-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 48

Registration Number: NCT03122717

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia
Blastic Plasmacytoid Dendritic Cell Neoplasm
Myelodysplastic Syndrome

Interventions: Drug: Azacitidine
Drug: SL-401
Drug: Venetoclax

First Posted Date: 2017-04-13

Last Posted Date: 2024-06-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 72

Registration Number: NCT03113643

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: LY3022855
Drug: Vemurafenib
Drug: Cobimetinib

First Posted Date: 2017-04-05

Last Posted Date: 2024-07-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT03101254

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Radium-223
Drug: Pembrolizumab

First Posted Date: 2017-03-28

Last Posted Date: 2024-11-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT03093428

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Leuprolide Acetate
Drug: Prednisone
Drug: Docetaxel
Drug: Apalutamide

First Posted Date: 2017-03-28

Last Posted Date: 2020-04-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 9

Registration Number: NCT03093272

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Phase 2

Completed

Conditions: Adenoid Cystic Carcinoma

Interventions: Radiation: Radiation
Drug: Pembrolizumab

First Posted Date: 2017-03-22

Last Posted Date: 2022-10-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT03087019

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

Phase 2

Active, not recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: Pembrolizumab
Radiation: Radiation

First Posted Date: 2017-03-21

Last Posted Date: 2024-01-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT03085719

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Phase 2

Suspended

Conditions: Mesothelioma

Interventions: Drug: Tremelimumab
Drug: Durvalumab

First Posted Date: 2017-03-09

Last Posted Date: 2024-01-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT03075527

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy